Treatment of inflammatory diseases using placental stem cells

Patent metadata

Field	Value
Publication number	US-11723930-B2
Application number	US-202016752326-A
Country	US
Kind code	B2
Filing date	Jan 24, 2020
Priority date	Feb 12, 2007
Publication date	Aug 15, 2023
Grant date	Aug 15, 2023

Abstract

Provided herein are methods of treatment of individuals having an immune-related disease, disorder or condition, for example, inflammatory bowel disease, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (Alibert-Bazin syndrome), or scleroderma using placental stem cells or umbilical cord stem cells.

First claim

What is claimed:

1. A method of treating an individual having or at risk of developing a disease, disorder or condition associated with or caused by an inappropriate or unwanted immune response, comprising administering to the individual a therapeutically effective amount of placental stem cells, or culture medium conditioned by placental stem cells, wherein the therapeutically effective amount is an amount sufficient to cause a detectable improvement in one or more symptoms of said disease, disorder or condition, wherein said disease, disorder or condition is scleroderma, and wherein said placental stem cell is a CD10+, CD34−, CD105+, CD200+ placental stem cell.

2. The method of claim 1 , wherein said placental stem cells express CD200 and HLA-G, or express CD73, CD105, and CD200, or express CD200 and OCT-4, or express CD73, CD105 and HLA-G, or express CD73 and CD105 and facilitate the formation of one or more embryoid-like bodies in a population of placental cells comprising said stem cell when said population is cultured under conditions that allow for the formation of an embryoid-like body, or express OCT-4 and facilitate the formation of one or more embryoid-like bodies in a population of placental cells comprising said stem cell when said population is cultured under conditions that allow for the formation of an embryoid-like body.

3. The method of claim 1 , comprising administering a second therapeutic agent to said individual.

4. The method of claim 3 , wherein said second therapeutic agent is an anti-inflammatory drug, a proton pump inhibitor, an immunosuppressant compound, or a vasodilator.

5. The method of claim 3 , wherein said second therapeutic agent is an anti-inflammatory drug, an immunosuppressant compound, exposure to sunlight, exposure to ultraviolet light, a topical steroid, local superficial radiotherapy, total skin electron beam radiation, application of organic honey to skin affected by erythroderma, an interferon, a retinoid, a rexinoid, or vorinostat.

Assignees

• Celularity Inc

Inventors

• Edinger James W
• Hariri Robert J
• Wang Jia-Lun
• Ye Qian
• Faleck Herbert

Classifications

• A61K35/50 Primary

  Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells · CPC title

• A61K35/644

  Beeswax; Propolis; Royal jelly; Honey · CPC title

• A61K38/21

  Interferons {[IFN]} · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• C12N5/0605

  Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly · CPC title